Abstract:Background: The incidence of clear cell renal cell carcinoma (ccRCC) is increasing worldwide, contributing to 70–85% of kidney cancer cases. Ferroptosis is a novel type of programmed cell death and could predict prognoses in cancers. Here, we developed a ferroptosis-related long non-coding RNA (FRlncRNA) signature to improve the prognostic prediction of ccRCC. Methods: The transcriptome profiles of FRlncRNAs and clinical data of ccRCC were obtained from The Cancer Genome Atlas and ICGC databases. Patients were randomly assigned to training cohorts, testing cohorts, and overall cohorts. The FRlncRNA signature was constructed by Lasso regression and Cox regression analysis, and Kaplan–Meier (K-M) analysis was used to access the prognosis of each group. The accuracy of this signature was evaluated by the receiver operating characteristic (ROC) curve. The visualization of functional enrichment was carried out by the gene set enrichment analysis (GSEA). Internal and external datasets were performed to verify the FRlncRNA signature. Results: A FRlncRNA signature comprising eight lncRNAs (AL590094.1, LINC00460, LINC00944, AC024060.1, HOXB-AS4, LINC01615, EPB41L4A-DT, and LINC01550) was identified. Patients were divided into low- and high-risk groups according to the median risk score, in which the high-risk group owned a dramatical shorter survival time than that of the low-risk group. Through ROC analysis, it was found that this signature had a greater predictive capability than traditional evaluation methods. The risk score was an independent risk factor for overall survival suggested by multivariate Cox analysis (HR = 1.065, 95%CI = 1.036–1.095, and p < 0.001). We constructed a clinically predictive nomogram based on this signature and its clinical features, which is of accurate prediction about the survival rate of patients. The GSEA showed that primary pathways were the P53 signaling pathway and tumor necrosis factor–mediated signaling pathway. The major FRlncRNAs (LINC00460, LINC00944, LINC01550, and EPB41L4A-DT) were verified with the prognosis of ccRCC in the GEPIA and K-M Plotter databases. Their major target genes (BNIP3, RRM2, and GOT1) were closely related to the stage, grade, and survival outcomes of ccRCC by the validation of multiple databases. Additionally, we found two groups had a significant distinct pattern of immune function, immune checkpoint, and immune infiltration, which may lead to different survival benefits. Conclusions: The FRlncRNA signature was accurate and act as reliable tools for predicting clinical outcomes and the immune microenvironment of patients with ccRCC, which may be molecular biomarkers and therapeutic targets.

Identification of the Ferroptosis-Related Long Non-Coding RNAs Signature to Improve the Prognosis Prediction and Immunotherapy Response in Patients with NSCLC

Identification and Validation of Ferroptosis-Related Lncrna Signatures As a Novel Prognostic Model for Glioma

A Novel Ferroptosis-Related Gene Signature Can Predict Prognosis and Influence Immune Microenvironment in Acute Myeloid Leukemia.

Identification of Ferroptosis-Related Lncrnas for Predicting Prognosis and Immunotherapy Response in Non-Small Cell Lung Cancer

Identification of a Ferroptosis-related lncRNA Signature for Prognosis Prediction in Lung Squamous Cell Carcinoma

A Ferroptosis-Related Lncrnas Signature for Prognosis Prediction and Its Relationship with Immune Microenvironment in Colon Adenocarcinoma

Identification and Validation of a Ferroptosis-Related Long Non-Coding RNA (FRlncRNA) Signature to Predict Survival Outcomes and the Immune Microenvironment in Patients With Clear Cell Renal Cell Carcinoma

Molecular Identification of an Immunity- and Ferroptosis-related Gene Signature in Non-Small Cell Lung Cancer

A Prognostic Ferroptosis-Related lncRNAs Signature Associated With Immune Landscape and Radiotherapy Response in Glioma

Establishment and validation of a ferroptosis-related signature predicting prognosis and immunotherapy effect in colon cancer

Construction and Validation of a Ferroptosis-Related lncRNA Signature as a Novel Biomarker for Prognosis, Immunotherapy and Targeted Therapy in Hepatocellular Carcinoma

A Novel Ferroptosis-Related Gene Signature for Predicting Outcomes in Cervical Cancer

A Ferroptosis-Related lncRNAs Signature Predicts Prognosis and Immune Microenvironment for Breast Cancer

Identification of a Novel Ferroptosis-Related Gene Signature for Predicting Prognosis and Responsiveness to Immunotherapy in Hepatocellular Carcinoma

A New Ferroptosis-Related Lncrna Signature Predicts the Prognosis of Bladder Cancer Patients.

Identification of Clinical Prognostic Regulators and Analysis of Ferroptosis-Related Signatures in the Tumor Immune Microenvironment in Lung Squamous Cell Carcinoma

Identification and Validation of a Ferroptosis-Related Long Non-coding RNA Signature for Predicting the Outcome of Lung Adenocarcinoma

Prediction of Prognosis and Molecular Mechanism of Ferroptosis in Hepatocellular Carcinoma Based on Bioinformatics Methods

Ferroptosis-related lncRNAs signature to predict the survival and immune evasion for lung squamous cell carcinoma

Identification of Ferroptosis-Related Signature with Potential Implications in Prognosis and Immunotherapy of Renal Cell Carcinoma

A ferroptosis-related gene signature and immune infiltration for predicting the lymph node metastasis of patients with lung adenocarcinoma